Robert R. Lavieri

Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity

Jana A. Lewis, Sarah Scott, Robert R. Lavieri et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 98 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Design, Synthesis, and Biological Evaluation of Halogenated <i>N</i>-(2-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: Discovery of an Isoform-Selective Small Molecule Phospholipase D2 Inhibitor

Robert R. Lavieri, Sarah Scott, Paige E. Selvy et al. · Journal of Medicinal Chemistry · 2010 · 90 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity

Robert R. Lavieri, Sarah Scott, Jana A. Lewis et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 66 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19

Wesley H. Self, Matthew S. Shotwell, Kevin W. Gibbs et al. · JAMA · 2023 · 54 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Discovery of Desketoraloxifene Analogues as Inhibitors of Mammalian, <i>Pseudomonas aeruginosa</i>, and NAPE Phospholipase D Enzymes

Sarah Scott, C. Thomas Spencer, Matthew C. O’Reilly et al. · ACS Chemical Biology · 2014 · 48 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +9